These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32672255)

  • 1. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives.
    Foulkes R; Man E; Thind J; Yeung S; Joy A; Hoskins C
    Biomater Sci; 2020 Sep; 8(17):4653-4664. PubMed ID: 32672255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating nanomedicine - can the FDA handle it?
    Bawa R
    Curr Drug Deliv; 2011 May; 8(3):227-34. PubMed ID: 21291376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Insights into the Biological Effects of Engineered Nanomaterials: A Focus on Gold Nanoparticles.
    Nguyen NHA; Falagan-Lotsch P
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
    Bobo D; Robinson KJ; Islam J; Thurecht KJ; Corrie SR
    Pharm Res; 2016 Oct; 33(10):2373-87. PubMed ID: 27299311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
    Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
    Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smart nano-micro platforms for ophthalmological applications: The state-of-the-art and future perspectives.
    Lyu Q; Peng L; Hong X; Fan T; Li J; Cui Y; Zhang H; Zhao J
    Biomaterials; 2021 Mar; 270():120682. PubMed ID: 33529961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials".
    de Vlieger JSB; Crommelin DJA; Tyner K; Drummond DC; Jiang W; McNeil SE; Neervannan S; Crist RM; Shah VP
    AAPS J; 2019 Apr; 21(4):56. PubMed ID: 30997588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the development of nanoparticle-based imaging agents: Characterization and biology.
    Crist RM; Dasa SSK; Liu CH; Clogston JD; Dobrovolskaia MA; Stern ST
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1665. PubMed ID: 32830448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
    Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
    Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
    Chowdhury N
    Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Strategies in the Design of Nanomedicines to Oppose Uptake by the Mononuclear Phagocyte System and Enhance Cancer Therapeutic Efficacy.
    Zhou Y; Dai Z
    Chem Asian J; 2018 Nov; 13(22):3333-3340. PubMed ID: 29441706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of nanomaterials: implications for nanomedicine.
    Nyström AM; Fadeel B
    J Control Release; 2012 Jul; 161(2):403-8. PubMed ID: 22306428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine and its applications to the treatment of prostate cancer.
    Ouvinha de Oliveira R; de Santa Maria LC; Barratt G
    Ann Pharm Fr; 2014 Sep; 72(5):303-16. PubMed ID: 25220226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.